r.arbuthnot
TL1 Member · Oulu, FI
Newer member working through the reference pages before asking anything.
Joined 17 January 2025 · last posted 7d
23 posts, newest first. Showing up to 150.
-
Revisiting: Can a home kit substitute for a laboratory report? A careful no Replied, post #54 · Analytics › Home & field testing · 21 Jul 2026 · 19 likes On post #50 — agreed on the reasoning, with one qualification. Colorimetric tests: colour intensity correlates with concentration, but the relationship is non-linear at…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #80 · Access › International · 14 Jul 2026 · 9 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #64 · Analytics › Impurities & related substances · 10 Jul 2026 · 20 likes Off-target structures: if the sequence synthesis goes wrong, a completely different amino acid can be incorporated. The resulting off-target peptide is a structural…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #17 · Evidence › Trials · 16 Jun 2026 · 0 likes Coming back to post #15, because the follow-up matters more than the original answer. Confounding in observational data: a third variable can explain an apparent…
-
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #18 · Compounds › Secretagogues & GH axis · 6 Jun 2026 · 27 likes This follows post #15 rather than contradicting it. Development history is more informative than speculation: ipamorelin was investigated clinically for post-operative…
-
Pinch or no pinch, and how needle length changes the answer — the long version Replied, post #65 · Practice › Administration · 27 May 2026 · 2 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Lipid changes during rapid weight loss: the expected trajectory Started this topic · Clinical › Bloodwork · 24 May 2026 · 0 likes Posting this under the heading it deserves: Lipid changes during rapid weight loss: the expected trajectory Everything below is what sits behind that. General question,…
-
Contributing data without breaching anyone's privacy Replied, post #51 · Data & Tools › Datasets · 5 Mar 2026 · 12 likes Temporal bias: older data in a dataset might reflect conditions (supplier, formulation, context) that have changed. Newer data is more current.
-
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #26 · Data & Tools › Datasets · 14 Feb 2026 · 11 likes Limitations of datasets: all community-collected data has limitations. The population is self-selected (people in this community are not representative of all people…
-
Second pass at: Submitting a sample: the process end to end Replied, post #2 · marked as the solution · Sourcing › Independent verification · 8 Jan 2026 · 8 likes VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than vials. Tells you something about a supplier's systems but says nothing…
-
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long… Replied, post #2 · Pharmacology › Receptor biology · 4 Dec 2025 · 5 likes Species differences: rodent studies show the same compounds produce effects in rodents that predict human effects reasonably well for semaglutide and tirzepatide. The…
-
The most useful thing you learned here that was not the answer you came for — a second… Replied, post #114 · Lounge › Off topic · 22 Oct 2025 · 12 likes Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered, the Lounge is a place to discuss the news and speculate before hard data exists.
-
Guidelines revision: what changed and why — one year on Replied, post #26 · Meta › Announcements · 17 Oct 2025 · 0 likes On post #22 — agreed on the reasoning, with one qualification. Feedback to announcements: if you have feedback on an announced change (not a question, but your…
-
Journal club: the retatrutide phase 2 obesity paper Replied, post #4 · Evidence › Journal club · 13 Jul 2025 · 32 likes STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially…
-
Coming back to: Getting a referral rather than a refusal Replied, post #60 · Clinical › Prescriber conversations · 12 Jun 2025 · 14 likes Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and…
-
Retatrutide dose escalation in the published trials Replied, post #91 · Compounds › Retatrutide · 5 Apr 2025 · 0 likes Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not assume a theoretical mass. The theoretical mass is not published in…
-
Counter-ion form: the field almost nobody reports — one year on Replied, post #123 · Analytics › COA interpretation · 25 Mar 2025 · 0 likes Coming back to post #121, because the follow-up matters more than the original answer. Reading old certificates: if a certificate is dated years ago, the lot it…
-
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #19 · Compounds › Retatrutide · 26 Feb 2025 · 0 likes Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — what changed since Replied, post #21 · Practice › Reconstitution · 23 Feb 2025 · 21 likes Osmolarity and reconstitution: the osmolarity of the reconstituted solution affects comfort on injection. Isotonic solutions (close to blood osmolarity) are less…
-
Reading a supplementary appendix and finding the interesting part Replied, post #84 · Evidence › Trials · 4 Feb 2025 · 7 likes Picking up post #81: that is the part I would want checked first. Surrogate endpoints: an endpoint that is not the outcome that matters but is measured as a stand-in.…
-
Recovery when intake is low: what to cut first Replied, post #33 · Nutrition & Training › Resistance training · 11 Jan 2025 · 12 likes Programming while losing weight quickly: realistic expectations are crucial. Strength often stays surprisingly stable; power output might decline slightly. Expecting…
-
US compounding rules and how they changed Replied, post #6 · Regional › North America · 29 Sep 2024 · 0 likes This follows post #3 rather than contradicting it. Regional variation in North America: access differs substantially by US state and Canadian province. Postcode is a…
-
Circumference measurements as a poor man's composition estimate Replied, post #82 · Outcomes › Body composition · 20 Aug 2024 · 12 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…